FIGURE 2.
Treatment with riociguat alone or combined with 5-z-7oxozeaenol attenuates pulmonary hypertension in the Sugen 5426/hypoxia (SuHyp) rat model. (A) Mean pulmonary arterial pressure (mPAP), (B) diastolic PAP (dPAP) and (C) systolic PAP (sPAP) in control (NMX-Vh) and SuHyp rats treated with vehicle, 5Z-7-oxozeaenol (SuHyp-OXO; 3 mg·kg−1·day−1), riociguat (SuHyp-RIO; 3 mg·kg−1·day−1) or both drugs combined (SuHyp-OXO-RIO). (D) Representative PAP recordings in each treatment group. (E) Right systolic and (F) end-diastolic ventricular pressure (RVSP and RVEDP). (G) Fulton index (ratio between RV and left ventricle plus septum weight) and (H) right ventricular weight relative to total body weight in the different treatment groups. Each bar shows the mean +SEM (n = 6–10 animals in each group). *p < 0.05 versus NMX-Vh and #p < 0,05 versus SuHyp vehicle (One-way ANOVA followed by Bonferroni´s post hoc test).